Thrombotic microangiopathy associated with interferon beta.
作者信息
Hunt David, Kavanagh David, Drummond Iain, Weller Belinda, Bellamy Chris, Overell James, Evans Stephen, Jackson Andrew, Chandran Siddharthan
机构信息
Edinburgh University, Edinburgh, United Kingdom.
出版信息
N Engl J Med. 2014 Mar 27;370(13):1270-1. doi: 10.1056/NEJMc1316118.
Abstract
摘要
相似文献
1
Thrombotic microangiopathy associated with interferon beta.与β-干扰素相关的血栓性微血管病
N Engl J Med. 2014 Mar 27;370(13):1270-1. doi: 10.1056/NEJMc1316118.
2
Renal thrombotic microangiopathy caused by interferon beta-1a treatment for multiple sclerosis.干扰素β-1a治疗多发性硬化症所致的肾血栓性微血管病。
Drug Des Devel Ther. 2013 Aug 7;7:723-8. doi: 10.2147/DDDT.S42138. eCollection 2013.
3
Interferon-beta in multiple sclerosis causing thrombotic microangiopathy.β-干扰素在多发性硬化症中引发血栓性微血管病。
Intern Med J. 2019 Feb;49(2):274-276. doi: 10.1111/imj.14204.
4
Comment on thrombotic microangiopathy induced by interferon-β therapy.
Clin Nephrol. 2012 Dec;78(6):506-7. doi: 10.5414/cn107623.
5
Thrombotic microangiopathy induced by long-term interferon-β therapy for multiple sclerosis: a case report.长期使用干扰素-β治疗多发性硬化症所致血栓性微血管病：一例报告
Clin Nephrol. 2011 Nov;76(5):396-400. doi: 10.5414/cn106523.
6
[Interferon ß, nephrotic syndrome and thrombotic microangiopathy].[干扰素β、肾病综合征与血栓性微血管病]
Med Clin (Barc). 2015 Jan 20;144(2):65-6. doi: 10.1016/j.medcli.2014.09.008. Epub 2014 Nov 20.
7
Thrombotic microangiopathy due to acquired complement factor I deficiency in a male receiving interferon-beta treatment for multiple sclerosis.一名接受干扰素-β治疗多发性硬化症的男性因获得性补体因子I缺乏症导致血栓性微血管病。
Br J Clin Pharmacol. 2023 May;89(5):1682-1685. doi: 10.1111/bcp.15631. Epub 2022 Dec 23.
8
A case of malignant hypertension with thrombotic microangiopathy.
Intern Med J. 2018 Mar;48(3):361-362. doi: 10.1111/imj.13724.
9
Favorable outcome of interferon-beta associated thrombotic microangiopathy following treatment with corticosteroids, plasma exchange and rituximab: A case report.干扰素-β相关性血栓性微血管病经皮质类固醇、血浆置换和利妥昔单抗治疗后结局良好：一例报告。
Mult Scler Relat Disord. 2016 Nov;10:63-65. doi: 10.1016/j.msard.2016.09.002. Epub 2016 Sep 6.
10
Malignant hypertension as a rare cause of thrombotic microangiopathy.恶性高血压作为血栓性微血管病的罕见病因。
BMJ Case Rep. 2017 Jun 8;2017:bcr-2017-220457. doi: 10.1136/bcr-2017-220457.
引用本文的文献
1
Post-transplant Thrombotic Microangiopathy.移植后血栓性微血管病
J Am Soc Nephrol. 2025 May 1;36(5):940-951. doi: 10.1681/ASN.0000000645. Epub 2025 Jan 31.
2
The devolution of biosimilars regulations.生物类似药法规的下放。
Nat Biotechnol. 2025 Jan;43(1):19-22. doi: 10.1038/s41587-024-02497-5.
3
Thrombotic Microangiopathy as a Life-Threatening Complication of Long-Term Interferon Beta Therapy for Multiple Sclerosis: Clinical Phenotype and Response to Treatment-A Literature Review.血栓性微血管病作为多发性硬化症长期β-干扰素治疗的一种危及生命的并发症：临床表型及治疗反应——文献综述
J Clin Med. 2024 Mar 11;13(6):1598. doi: 10.3390/jcm13061598.
4
Apoptosis-resistant megakaryocytes produce large and hyperreactive platelets in response to radiation injury.辐射损伤时，抗凋亡巨核细胞产生体积大且反应过度的血小板。
Mil Med Res. 2023 Dec 19;10(1):66. doi: 10.1186/s40779-023-00499-z.
5
Multiple sclerosis: time for early treatment with high-efficacy drugs.多发性硬化症：是时候用高效药物进行早期治疗了。
J Neurol. 2024 Jan;271(1):105-115. doi: 10.1007/s00415-023-11969-8. Epub 2023 Oct 18.
6
Thrombotic Microangiopathy after a 15-year Treatment with Interferon Beta-1b in a Patient with Multiple Sclerosis: A Case Report and Review of Literature.一名多发性硬化症患者接受15年β-1b干扰素治疗后发生血栓性微血管病：病例报告及文献复习
Intern Med. 2024 Apr 15;63(8):1113-1117. doi: 10.2169/internalmedicine.1846-23. Epub 2023 Sep 1.
7
Drug-induced thrombotic microangiopathy: An updated review of causative drugs, pathophysiology, and management.药物性血栓性微血管病：致病药物、病理生理学及管理的最新综述
Front Pharmacol. 2023 Jan 9;13:1088031. doi: 10.3389/fphar.2022.1088031. eCollection 2022.
8
Case report: Thrombotic microangiopathy concomitant with macrophage activation syndrome in systemic lupus erythematosus refractory to conventional treatment successfully treated with eculizumab.病例报告：血栓性微血管病合并巨噬细胞活化综合征，在常规治疗无效的系统性红斑狼疮患者中，使用依库珠单抗成功治疗。
Front Med (Lausanne). 2023 Jan 9;9:1097528. doi: 10.3389/fmed.2022.1097528. eCollection 2022.
9
Emerging concepts of type I interferons in SLE pathogenesis and therapy.I 型干扰素在系统性红斑狼疮发病机制和治疗中的新观点。
Nat Rev Rheumatol. 2022 Oct;18(10):575-590. doi: 10.1038/s41584-022-00826-z. Epub 2022 Sep 12.
10
Renal diseases secondary to interferon-β treatment: a multicentre clinico-pathological study and systematic literature review.继发于干扰素-β治疗的肾脏疾病：一项多中心临床病理研究及系统文献综述
Clin Kidney J. 2021 Jul 6;14(12):2563-2572. doi: 10.1093/ckj/sfab114. eCollection 2021 Dec.
本文引用的文献
1
Safety and immunogenicity of a new formulation of interferon beta-1a (Rebif New Formulation) in a Phase IIIb study in patients with relapsing multiple sclerosis: 96-week results.干扰素β-1a新制剂（Rebif新制剂）在复发型多发性硬化症患者IIIb期研究中的安全性和免疫原性：96周结果
Mult Scler. 2009 Feb;15(2):219-28. doi: 10.1177/1352458508097299. Epub 2008 Aug 28.
2
Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group.皮下注射干扰素β-1a预防复发型/缓解型多发性硬化症复发和残疾的随机双盲安慰剂对照研究。PRISMS（皮下注射干扰素β-1a预防多发性硬化症复发和残疾）研究组。
Lancet. 1998 Nov 7;352(9139):1498-504.
Zotero 插件